Aegerion Warned for Touting Unapproved Uses of Cholesterol Drug on TV

Drug Industry Daily
A A
Aegerion Pharmaceuticals CEO Marc Beer’s televised comments about the company’s heart drug Juxtapid have drawn a warning letter from the FDA for failing to mention drug risks and promoting an off-label use.

To View This Article:

Login

Subscribe To Drug Industry Daily